Antibodies Responsible for Fetal Goiter, Hashimoto's, and Graves Disease
Anti-TSH receptor antibodies (TRAb) are responsible for both fetal goiter and Graves disease, while anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibodies (TGAb) are the primary antibodies in Hashimoto's thyroiditis.
Graves Disease
Thyroid-stimulating immunoglobulins (TSI) are the pathogenic antibodies in Graves disease. These are a subset of anti-TSH receptor antibodies (TRAb) that have stimulatory activity on the TSH receptor 1. The key mechanism is:
- TSI binds to and activates the TSH receptor
- This causes thyroid gland stimulation and hyperthyroidism
- These antibodies can cross the placenta during pregnancy
Important clinical distinction: While TRAb assays detect all TSH receptor antibodies (both stimulating and blocking), TSI specifically measures the stimulatory subset. In practice, 2nd generation radioreceptor TRAK assays for anti-TSH-R antibodies are routinely used and sufficient to identify risk 1.
Fetal Goiter
Fetal goiter results from transplacental passage of maternal anti-TSH-R antibodies in mothers with Graves disease 1. The pathophysiology involves:
- Fetal hyperthyroidism: TSH receptor stimulation by maternal TSI after 20 weeks gestation (when fetal TSH receptors become functional) causes thyroid overstimulation and goiter 1
- Fetal hypothyroidism: Transplacental passage of antithyroid drugs can cause goiter with hypothyroidism 1
Critical threshold: Anti-TSH-R antibody levels exceeding 5 IU/L in the 2nd trimester indicate significant risk for fetal and neonatal hyperthyroidism 1. There is a 15% risk of fetal thyroid dysfunction when maternal anti-TSH-R antibodies are present 1.
Rare exception: Anti-thyroid peroxidase antibodies (TPOAb) from maternal Hashimoto's thyroiditis can rarely cross the placenta and cause congenital goiter with hypothyroidism, though this is extremely uncommon (incidence 1:31,000-1:84,700) 2.
Hashimoto's Thyroiditis
Anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibodies (TGAb) are the hallmark antibodies of Hashimoto's thyroiditis 3. The mechanism differs fundamentally from Graves disease:
- TPOAb and TGAb target thyroid tissue components
- These cause lymphocytic infiltration, fibrosis, and epithelial cell destruction
- Approximately 10% of patients with positive TPOAb/TGAb develop hypothyroidism 3
Important subset: Some Hashimoto's patients also have TSH-stimulation blocking antibodies (TSBAb), which are a type of TRAb that blocks rather than stimulates the TSH receptor 3. These patients develop:
- Thyroid atrophy (not goiter)
- Hypothyroidism from receptor blockade
Clinical overlap: About 76% of Hashimoto's patients have detectable TSH receptor-binding antibodies, though these are typically non-stimulating or blocking types, unlike the stimulatory antibodies in Graves disease 4.
Key Clinical Distinctions
The functional effect of antibodies determines the clinical picture:
- Stimulating TRAb (TSI) → Graves disease with hyperthyroidism
- Blocking TRAb (TSBAb) → Atrophic thyroiditis with hypothyroidism
- TPOAb/TGAb → Hashimoto's thyroiditis with goitrous hypothyroidism
- Maternal TRAb crossing placenta → Fetal goiter (hyper- or hypothyroidism depending on balance with antithyroid drugs)
Critical caveat for pregnancy: Even after definitive treatment (radioiodine or thyroidectomy) for Graves disease, TRAb can persist and cross the placenta, causing fetal hyperthyroidism despite the mother being euthyroid or hypothyroid on replacement therapy 5, 6. This requires monitoring throughout pregnancy in any woman with current or past Graves disease 7, 8.